Protagonist Therapeutics (PTGX) Income from Continuing Operations (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Income from Continuing Operations of 3783000.0 for Q1 2026, up 132.46% on a YoY basis from 1627389.55 in Q1 2025, and up 108.52% sequentially from 44384000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Income from Continuing Operations data on file, last reported at 3783000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 132.46% year-over-year to 3783000.0; the trailing twelve-month figure through Mar 2026 stood at 114739000.0 (down 304.31% YoY), and the FY2025 full-year result was 130149000.0, down 147.3% from the prior year.
- Income from Continuing Operations improved to 3783000.0 in Q1 2026, from 44384000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 207366000.0 in Q1 2024 to a low of 66943000.0 in Q1 2022.
- A 5-year average of 5386941.18 and a median of 33725000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 178.95% in 2022 and jumped 714.87% in 2024, its largest moves.
- Tracing PTGX's Income from Continuing Operations over 5 years: stood at 34940000.0 in 2022, then soared by 225.69% to 43915000.0 in 2023, then jumped by 199.7% to 131615000.0 in 2024, then slumped by 133.72% to 44384000.0 in 2025, then surged by 108.52% to 3783000.0 in 2026.
- Business Quant data shows PTGX's Income from Continuing Operations at 3783000.0 in Q1 2026, 44384000.0 in Q4 2025, and 39339000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | -44.38 Mn |
| Sep 30, 2025 | -39.34 Mn |
| Jun 30, 2025 | -34.80 Mn |
| Mar 31, 2025 | -11.66 Mn |
| Dec 31, 2024 | 131.62 Mn |
| Sep 30, 2024 | -33.21 Mn |
| Jun 30, 2024 | -30.59 Mn |
| Mar 31, 2024 | 207.37 Mn |
| Dec 31, 2023 | 43.92 Mn |
| Sep 30, 2023 | -34.11 Mn |
| Jun 30, 2023 | -38.46 Mn |
| Mar 31, 2023 | -33.73 Mn |
| Dec 31, 2022 | -34.94 Mn |
| Sep 30, 2022 | -33.45 Mn |
| Jun 30, 2022 | -42.66 Mn |
| Mar 31, 2022 | -66.94 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -33.80 Mn |
| Jun 30, 2021 | -30.84 Mn |